Results 231 to 240 of about 1,103,489 (292)

Hemolytic Disease of the Fetus and Newborn: Fetal RHD Genotyping, Targeted Prophylaxis, and Prenatal Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Hemolytic disease of the fetus and newborn (HDFN) remains a significant concern in prenatal care primarily caused by maternal alloimmunization against fetal red blood cell antigens, most commonly the D antigen. Noninvasive fetal RHD genotyping, used as a screening tool, enables targeted antenatal prophylaxis and has been implemented in several
Emilie Thorup, Steffen Thorsen, Morten Hanefeld Dziegiel, Olav Bjørn Petersen, Frederik Banch Clausen   +4 more
wiley   +1 more source

The association between different aspects of socioeconomic deprivation and severe maternal morbidity. [PDF]

Acta Obstet Gynecol Scand
Geddes-Barton D, Ramakrishnan R, Goldacre R, Knight M.   +3 more
europepmc   +1 more source

Attitudes Toward Prenatal Interventions in the Fanconi Anemia Community

Prenatal Diagnosis, EarlyView.
ABSTRACT Objective In‐utero cell and gene therapies may offer prenatal treatment options for inherited diseases. Preclinical data suggests in‐utero (IU) hematopoietic stem cell transplantation (HSCT) could prevent Fanconi anemia (FA) related bone marrow failure without genotoxic conditioning or immune suppression.
Tony Lum, Catherine Lee, Tippi MacKenzie, Billie Lianoglou, Agnieszka Czechowicz   +4 more
wiley   +1 more source

Operationalization of Severe Maternal Morbidity surveillance in administrative databases of the Brazilian public and private health systems: Brazil 2015-2022. [PDF]

PLoS One
Domingues RMSM, Dias MAB, Guillen LCT, Pinheiro RS, Saraceni V, Coeli CM.   +5 more
europepmc   +1 more source

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source

Ranked Severe Maternal Morbidity Index for Population-Level Surveillance by Mode of Delivery. [PDF]

J Womens Health (Larchmt)
Womack LS, Galang RR, Admon LK, Clark EA, Ewing AC, Satten GA, Ko JY, Ferre CD, Kroelinger CD.   +8 more
europepmc   +1 more source

Assessing the Role of Cardiac Disease in Severe Maternal Morbidity: A Population-Based Cohort Study. [PDF]

O G Open
Darmawan KF, Sherwin EB, Leonard SA, Panelli DM, Mayo JA, Girsen AI, Carmichael SL, Khandelwal A, Bianco K.   +8 more
europepmc   +1 more source

The impact of metal cup size on neonatal and maternal morbidity in vacuum-assisted deliveries. [PDF]

Int J Gynaecol Obstet
Anteby M, Pinchas-Cohen T, Baruch Y, Lavie A, Maslovitz S, Hiersch L, Yogev Y.   +6 more
europepmc   +1 more source

Diagnosed Polycystic Ovary Syndrome and Associated Severe Maternal Morbidity.

Gynecol Obstet Invest
Hincapie MA, Ray JG, Shellenberger J, Velez MP.   +3 more
europepmc   +1 more source